TuHURA Biosciences Retained Earnings (Accumulated Deficit) 2010-2024 | HURA

TuHURA Biosciences retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

TuHURA Biosciences Retained Earnings (Accumulated Deficit) 2010-2024 | HURA

TuHURA Biosciences retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.8B
Vertex Pharmaceuticals (VRTX)$122.6B
Gilead Sciences (GILD)$109.8B
Bristol Myers Squibb (BMY)$107B
Regeneron Pharmaceuticals (REGN)$106.1B
CSL (CSLLY)$96.1B
GSK (GSK)$78.8B
Alnylam Pharmaceuticals (ALNY)$38.1B
Argenex SE (ARGX)$34B
Biogen (BIIB)$27.1B
BioNTech SE (BNTX)$26.4B
Illumina (ILMN)$22.9B
BeiGene (BGNE)$21.5B
Moderna (MRNA)$20.5B
Genmab (GMAB)$15.1B
BioMarin Pharmaceutical (BMRN)$13.4B
Exact Sciences (EXAS)$13B
Insmed (INSM)$12.7B
Incyte (INCY)$12.6B
Vaxcyte (PCVX)$12.6B
Sarepta Therapeutics (SRPT)$12.2B
Bio-Techne Corp (TECH)$11.1B
QIAGEN (QGEN)$9.6B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.7B
Exelixis (EXEL)$8.2B
Legend Biotech (LEGN)$8.2B
Intra-Cellular Therapies (ITCI)$8.1B
Repligen (RGEN)$8.1B
Revolution Medicines (RVMD)$7.9B